Paolo Tarantino/X
Feb 20, 2025, 09:22
Paolo Tarantino: Letter on the DB06 trial by ASCO/CAP members is out
Paolo Tarantino, Advanced research fellow at Dana-Farber Cancer Institute, shared a post on X:
“Letter on the DB06 trial by ASCO/CAP members out in NEJM. Recommendation to report HER2 IHC 0 as ‘with no staining’ or ‘with staining’ to ascertain eligibility for T-DXd. Call to action for the sponsors to share specimens for testing quantitative assays.”
“Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer”
More posts featuring Paolo Tarantino.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 26, 2025, 15:14
Mar 26, 2025, 15:07
Mar 26, 2025, 14:53
Mar 26, 2025, 14:43
Mar 26, 2025, 14:26
Mar 26, 2025, 14:11
Mar 26, 2025, 14:01